Fatty Acid Synthesis and Regulation - Biochemistry

SECTION 1

Historical Context & Motivation

The question of how living organisms manufacture fat from dietary carbohydrates fascinated biochemists long before the enzymatic machinery was identified. Early metabolic tracer experiments in the mid-twentieth century revealed that the pathway for fatty acid synthesis (lipogenesis) is distinct from β-oxidation, the catabolic route that degrades fatty acids. This observation overturned the simplistic assumption that biosynthesis was merely the reverse of degradation, and it launched decades of research into the enzymes, coenzymes, and regulatory mechanisms that govern de novo lipogenesis. Understanding these discoveries in chronological order clarifies why the pathway operates the way it does and why its regulation is so medically relevant.

1940s • Isotope Tracer Studies

Rudolf Schoenheimer and David Rittenberg used deuterium-labeled compounds to demonstrate that fatty acids are in constant metabolic flux, not static storage molecules, setting the stage for pathway elucidation.

1958 • Discovery of Acetyl-CoA Carboxylase

Salih Wakil identified acetyl-CoA carboxylase (ACC) and showed that malonyl-CoA, not acetyl-CoA alone, is the immediate two-carbon donor for chain elongation.

1960s • Fatty Acid Synthase Characterized

P. Roy Vagelos and colleagues purified the multienzyme fatty acid synthase (FAS) complex in E. coli, revealing the acyl carrier protein (ACP) as a central tethering scaffold.

1970s–1980s • Hormonal Regulation Elucidated

The roles of insulin, glucagon, and AMP-activated protein kinase (AMPK) in controlling ACC activity through phosphorylation were mapped, connecting lipogenesis to whole-body energy status.

1993 • SREBP Transcription Factors Discovered

Michael Brown and Joseph Goldstein identified sterol regulatory element-binding proteins (SREBPs), revealing how cells sense cholesterol and fatty acid levels to transcriptionally upregulate lipogenic genes.

These discoveries converged on a central question that still drives research today: how does a cell coordinate the energetically expensive production of fatty acids with the availability of substrates and the organism's overall energy balance? Answering that question requires a detailed understanding of the enzymatic steps of de novo synthesis, the transport of carbon from mitochondria to the cytosol, and the multilayered regulatory circuits—allosteric, covalent, and transcriptional—that modulate pathway flux.

SECTION 2

Core Principles of Fatty Acid Synthesis

De novo fatty acid synthesis converts excess acetyl-CoA into the 16-carbon saturated fatty acid palmitate (C16:0) in the cytosol of hepatocytes and adipocytes. The pathway consumes ATP, NADPH, and bicarbonate, and it relies on two key enzymes: acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS). Several foundational ideas underpin the entire pathway.

Compartmentalization

Synthesis occurs in the cytosol, whereas β-oxidation takes place in the mitochondrial matrix. This spatial separation allows independent regulation of the two opposing pathways.

Citrate Shuttle

Acetyl-CoA cannot cross the inner mitochondrial membrane directly. Instead, it condenses with oxaloacetate to form citrate, which is exported and cleaved by ATP-citrate lyase in the cytosol.

Malonyl-CoA as the C₂ Donor

ACC carboxylates acetyl-CoA to malonyl-CoA. The release of CO₂ during each condensation step drives the reaction forward thermodynamically, making elongation essentially irreversible.

NADPH as Reductant

Each round of elongation requires two molecules of NADPH. The pentose phosphate pathway and the malic enzyme reaction supply the majority of cytosolic NADPH for lipogenesis.

Iterative 4-Step Cycle

FAS catalyzes a repeating cycle of condensation → reduction → dehydration → reduction, adding two carbons per cycle. Seven cycles convert one acetyl-CoA primer plus seven malonyl-CoA units into palmitate.

✦

KEY TAKEAWAY

Think of fatty acid synthesis as a factory assembly line. The citrate shuttle is the freight elevator bringing raw material (acetyl-CoA equivalents) from the basement (mitochondrion) to the production floor (cytosol). ACC is the quality-control gate that stamps each two-carbon unit with a CO₂ 'ticket' (forming malonyl-CoA), and FAS is the robotic assembler that bolts on two-carbon segments in a repeating four-step cycle. The CO₂ ticket is discarded at each weld, releasing energy that makes the joint permanent.

SECTION 3

The De Novo Fatty Acid Synthesis Pathway

Overview of de novo fatty acid synthesis. Acetyl-CoA generated in the mitochondrion is exported to the cytosol as citrate via the citrate shuttle. In the cytosol, ACC converts acetyl-CoA to malonyl-CoA, and FAS then executes seven iterative four-step cycles to produce palmitate (C16:0).

The diagram above traces the carbon flow from the mitochondrial matrix to the cytosol and through the two committed enzymatic steps. Within the mitochondrion, acetyl-CoA—produced primarily from pyruvate dehydrogenase—condenses with oxaloacetate (OAA) via citrate synthase to form citrate. When the citric acid cycle is saturated (i.e., cellular ATP and NADH are abundant), citrate accumulates and is exported through the mitochondrial citrate transporter. In the cytosol, ATP-citrate lyase regenerates acetyl-CoA and OAA at the expense of one ATP. The OAA is recycled back to the mitochondrion as malate (via malate dehydrogenase) or converted to pyruvate by malic enzyme, generating one molecule of NADPH in the process. This NADPH contributes to the reductive power required by FAS, alongside the pentose phosphate pathway, which supplies the bulk of the remaining NADPH.

Fatty acid synthase itself is a remarkable homodimeric multifunctional enzyme in mammals (type I FAS), with each polypeptide chain harboring seven distinct catalytic domains plus an acyl carrier protein (ACP) domain bearing a phosphopantetheine prosthetic group. Intermediates remain covalently tethered to the ACP thiol throughout the elongation cycle, ensuring substrate channeling and high catalytic efficiency. The cycle repeats seven times, adding two carbons per round, and the final product—palmitoyl-ACP—is released as free palmitate by the thioesterase domain.

SECTION 4

Stoichiometry and Energetics of Palmitate Synthesis

The overall stoichiometry of palmitate synthesis can be derived by summing the individual reactions of ACC and the seven FAS cycles. Understanding the energy cost clarifies why de novo lipogenesis is tightly regulated—it is one of the most ATP- and NADPH-intensive biosynthetic pathways in the cell.

ACC REACTION

Acetyl-CoA + CO₂ + ATP → Malonyl-CoA + ADP + Pᵢ

Biotin-dependent carboxylation. This reaction is the rate-limiting step of the entire pathway. One ATP is consumed per malonyl-CoA produced.

OVERALL STOICHIOMETRY

8 Acetyl-CoA + 7 ATP + 14 NADPH + 14 H⁺ → Palmitate + 8 CoA-SH + 7 ADP + 7 Pᵢ + 14 NADP⁺ + 6 H₂O

One acetyl-CoA serves as the primer; seven malonyl-CoA units (from 7 acetyl-CoA + 7 ATP + 7 CO₂) supply the remaining 14 carbons. Seven CO₂ molecules are released during condensation, canceling those consumed by ACC.

FULL ENERGETIC COST (INCLUDING CITRATE SHUTTLE)

Total cost per palmitate ≈ 7 ATP (ACC) + 8 ATP (citrate lyase) + 14 NADPH (FAS) + 2 NADPH (shuttle) = 15 ATP + 14 NADPH equivalents

When accounting for the ATP consumed by ATP-citrate lyase (8 citrate molecules cleaved to regenerate 8 acetyl-CoA) and the NADPH generated by malic enzyme, the effective cost per palmitate molecule becomes even higher. Each NADPH is worth approximately 2.5 ATP equivalents, bringing the total close to ~50 ATP-equivalents.

💡

Why CO₂ is Not Net Consumed

Students often ask why CO₂ appears on both sides of the ledger. ACC incorporates CO₂ into malonyl-CoA, but during each condensation on FAS, the same CO₂ is released as the malonyl group attacks the growing acyl chain. The decarboxylation provides the thermodynamic driving force (ΔG is strongly negative) without net consumption of CO₂. This is analogous to using a catapult's counterweight—the weight (CO₂) is reused each launch.

The 14 NADPH molecules required per palmitate are supplied primarily by two sources: the oxidative phase of the pentose phosphate pathway (glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase generate 2 NADPH per glucose-6-phosphate oxidized) and the cytosolic malic enzyme reaction (1 NADPH per OAA recycled). Thus, lipogenesis links carbohydrate catabolism, the pentose phosphate shunt, and the citrate shuttle into a coordinated metabolic network.

SECTION 5

Regulation of Fatty Acid Synthesis

Because palmitate synthesis is energetically expensive and occupies a pivotal position between carbohydrate and lipid metabolism, cells employ three tiers of regulation: allosteric, covalent (phosphorylation), and transcriptional. The primary regulatory target is ACC, the enzyme catalyzing the committed step.

Three tiers of ACC regulation. Allosteric control (left): citrate activates ACC by promoting polymerization into active filaments, while palmitoyl-CoA causes feedback inhibition. Covalent modification (right): AMPK and PKA phosphorylate and inactivate ACC; insulin-stimulated phosphatase PP2A dephosphorylates and reactivates it. Transcriptional regulation (bottom): SREBP-1c and ChREBP upregulate ACC and FAS genes over hours to days.

Allosteric Regulation

Citrate, which accumulates when the TCA cycle is saturated, serves as a feed-forward allosteric activator of ACC. Binding of citrate induces the inactive protomeric form of ACC to polymerize into long, enzymatically active filamentous structures. Conversely, the end product palmitoyl-CoA promotes depolymerization and feedback inhibition, thereby preventing futile overproduction of fatty acids when cellular acyl-CoA pools are replete.

Covalent Modification (Phosphorylation)

The energy-sensing kinase AMP-activated protein kinase (AMPK) phosphorylates ACC at Ser79 (in mammals), inactivating the enzyme. AMPK is activated when the AMP:ATP ratio rises, signaling low cellular energy—a state incompatible with energy-consuming biosynthesis. Similarly, glucagon-stimulated protein kinase A (PKA) phosphorylates ACC during fasting. Insulin opposes these kinases by activating protein phosphatase 2A (PP2A), which dephosphorylates ACC and restores its activity. This hormonal axis ensures that lipogenesis is active in the fed state and suppressed during fasting or exercise.

Transcriptional Control

Long-term changes in lipogenic capacity are mediated by transcription factors. SREBP-1c (sterol regulatory element-binding protein 1c) is activated by insulin signaling and upregulates genes encoding ACC, FAS, ATP-citrate lyase, and stearoyl-CoA desaturase. A second transcription factor, ChREBP (carbohydrate-responsive element-binding protein), responds to high glucose flux and independently stimulates lipogenic gene transcription. Together, SREBP-1c and ChREBP integrate hormonal and nutrient signals to tune the cell's biosynthetic capacity over hours to days.

SECTION 6

Worked Example: Calculating the Cost of Palmitate Synthesis

Let us work through the accounting of ATP and NADPH consumed in the synthesis of one molecule of palmitate from acetyl-CoA, starting from glucose as the carbon source.

How Many ATP Equivalents Does It Cost to Synthesize One Palmitate?

1
Step 1 — Count acetyl-CoA primer and malonyl-CoA units

Palmitate has 16 carbons. One acetyl-CoA (2C) primes the pathway. The remaining 14 carbons come from 7 malonyl-CoA molecules (each contributing 2C after loss of CO₂).

Total acetyl-CoA consumed = 1 (primer) + 7 (for malonyl-CoA) = 8 acetyl-CoA
2
Step 2 — ATP consumed by ACC

ACC carboxylates 7 acetyl-CoA to 7 malonyl-CoA, consuming 1 ATP per reaction.

ATP used by ACC = 7 ATP
3
Step 3 — NADPH consumed by FAS

Each of the 7 elongation cycles on FAS requires 2 NADPH (one for β-ketoacyl reduction, one for enoyl reduction).

NADPH used by FAS = 7 × 2 = 14 NADPH
4
Step 4 — ATP consumed by ATP-citrate lyase

Each of the 8 cytosolic acetyl-CoA molecules originated as mitochondrial citrate. ATP-citrate lyase consumes 1 ATP per citrate cleaved.

ATP used by citrate lyase = 8 ATP
5
Step 5 — Convert NADPH to ATP equivalents and sum

Each NADPH is roughly equivalent to 2.5 ATP (via oxidative phosphorylation if the cell diverted those electrons to the ETC). Adding the malic enzyme contribution of ~8 NADPH generated during OAA recycling partially offsets the requirement, but focusing on consumption: 14 NADPH × 2.5 = 35 ATP-equivalents. Total = 7 (ACC) + 8 (citrate lyase) + 35 (NADPH equivalents).

Total energetic cost ≈ 50 ATP-equivalents per palmitate

✦

KEY TAKEAWAY

Synthesizing one molecule of palmitate costs the cell roughly 50 ATP-equivalents. For perspective, complete oxidation of one glucose yields only about 30–32 ATP. This means the cell must oxidize more than 1.5 glucose molecules (just for energy) to fund the synthesis of a single 16-carbon fatty acid—a powerful reason why lipogenesis is only permitted in the well-fed state.

SECTION 7

Fatty Acid Synthesis vs. β-Oxidation

A common source of confusion in biochemistry is the relationship between fatty acid synthesis and β-oxidation. Although both pathways involve sequential two-carbon additions or removals, they are catalyzed by different enzymes, occur in different cellular compartments, use different cofactors, and are regulated reciprocally. The table below highlights the key distinctions.

Feature	Fatty Acid Synthesis	β-Oxidation
Location	Cytosol	Mitochondrial matrix
Acyl carrier	ACP (phosphopantetheine)	CoA-SH
C₂ unit	Malonyl-CoA (3C → 2C + CO₂)	Acetyl-CoA (2C released)
Redox cofactor	NADPH (reductant)	NAD⁺ and FAD (oxidants)
Energy	Consumes ATP (via ACC)	Generates ATP (via ETC)
Stereochemistry of β-hydroxy intermediate	D-β-hydroxyacyl	L-β-hydroxyacyl
Hormonal activation	Insulin (fed state)	Glucagon, epinephrine (fasting/exercise)
Key regulatory molecule	Malonyl-CoA (product of ACC)	Malonyl-CoA inhibits CPT-I entry

Comparison of de novo fatty acid synthesis and β-oxidation

✦

KEY TAKEAWAY

Malonyl-CoA is the linchpin that prevents the two pathways from running simultaneously. When ACC is active and malonyl-CoA levels are high (fed state), malonyl-CoA inhibits carnitine palmitoyltransferase I (CPT-I), blocking fatty acid entry into the mitochondrion for β-oxidation. This is a textbook example of reciprocal regulation: the very first committed intermediate of synthesis serves as the gatekeeper that shuts down degradation.

SECTION 8

Clinical Relevance and Advanced Connections

Dysregulation of fatty acid synthesis has direct clinical implications. In metabolic syndrome and non-alcoholic fatty liver disease (NAFLD), hepatic de novo lipogenesis is pathologically elevated due to chronic hyperinsulinemia and SREBP-1c overactivation. Conversely, pharmacological inhibition of FAS or ACC is being explored as a strategy to combat obesity and certain cancers where lipogenesis fuels rapid cell proliferation. The table below connects the biochemistry to advanced and clinical topics.

Concept	Basic (This Lesson)	Advanced / Clinical Extension
Product	Palmitate (C16:0)	Elongases and desaturases produce C18, C20 PUFAs; ω-3 and ω-6 essential fatty acids must be dietary
ACC isoforms	Single ACC activity discussed	ACC1 (cytosolic, lipogenesis) vs. ACC2 (mitochondrial membrane, CPT-I regulation); distinct therapeutic targets
FAS architecture	Mammalian type I FAS homodimer	Bacterial/plant type II FAS uses dissociable enzymes; target for antibiotic design (triclosan, isoniazid)
AMPK	Phosphorylates and inactivates ACC	Metformin (type 2 diabetes drug) activates AMPK → ↓ lipogenesis; exercise activates AMPK similarly
Cancer	Not discussed	Many tumors overexpress FAS (lipogenic phenotype); FAS inhibitors (TVB-2640) in clinical trials as anticancer agents

Connections from basic fatty acid synthesis to advanced and clinical topics

Looking forward, understanding de novo lipogenesis provides the biochemical foundation for courses in nutritional biochemistry, endocrinology, and pharmacology. The interplay between AMPK, mTORC1, and insulin signaling pathways illustrates how cells integrate growth signals with metabolic capacity, a theme that recurs throughout cell biology and molecular medicine.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why de novo fatty acid synthesis occurs in the cytosol rather than the mitochondrial matrix, even though the primary carbon source (acetyl-CoA) is generated in the mitochondrion. What advantage does this compartmentalization provide?

Show answer

Compartmentalization allows the cell to regulate synthesis and degradation independently. β-Oxidation occurs in the mitochondrial matrix using NAD⁺ and FAD as electron acceptors, while synthesis in the cytosol uses NADPH as the reductant. If both pathways were in the same compartment with the same cofactor pool, simultaneous operation would create a futile cycle, wasting ATP. Spatial separation, coupled with the malonyl-CoA inhibition of CPT-I, ensures that the two pathways are reciprocally controlled so the cell either builds or burns fat, but not both at the same time.

Question 2: BASIC CALCULATION

How many molecules of malonyl-CoA are required to synthesize one molecule of stearate (C18:0)? How many NADPH molecules does FAS consume for this product?

Show answer

Stearate has 18 carbons. One acetyl-CoA (2C) serves as the primer, leaving 16 carbons to be added. Each malonyl-CoA contributes 2 carbons (after CO₂ loss), so 16 ÷ 2 = 8 malonyl-CoA molecules are needed. FAS uses 2 NADPH per elongation cycle, and there are 8 cycles (one per malonyl-CoA addition), so 8 × 2 = 16 NADPH are consumed. Note that FAS itself produces only palmitate (C16:0); the extension from C16 to C18 is actually performed by elongase systems in the endoplasmic reticulum, which require an additional round of malonyl-CoA condensation and 2 NADPH, for a total of 8 + 1 = 9 malonyl-CoA and 16 + 2 = 18 NADPH if we include the ER elongation step.

Question 3: INTERMEDIATE

A patient with a genetic deficiency in glucose-6-phosphate dehydrogenase (G6PD) has impaired pentose phosphate pathway activity. Would you expect this patient's hepatic fatty acid synthesis rate to be affected? Explain your reasoning, considering alternative NADPH sources.

Show answer

Yes, hepatic fatty acid synthesis would likely be reduced. The oxidative phase of the pentose phosphate pathway, which includes G6PD and 6-phosphogluconate dehydrogenase, is a major supplier of cytosolic NADPH. Without adequate NADPH, FAS cannot carry out the two reductive steps in each elongation cycle. While the malic enzyme reaction and cytosolic isocitrate dehydrogenase (NADP⁺-dependent) can partially compensate, these sources alone are typically insufficient to meet the full demand of 14 NADPH per palmitate. The degree of impairment would depend on the severity of the G6PD deficiency and the tissue's reliance on the PPP versus alternative NADPH-generating routes.

Question 4: APPLIED

Metformin, a widely prescribed type 2 diabetes drug, activates AMPK. Using your knowledge of fatty acid synthesis regulation, predict the effect of metformin on (a) ACC activity, (b) malonyl-CoA concentration, (c) CPT-I activity, and (d) hepatic fatty acid synthesis rate. Briefly explain the clinical benefit of each change.

Show answer

(a) AMPK phosphorylates ACC at Ser79, inactivating it. ACC activity decreases. (b) With ACC inactive, less acetyl-CoA is carboxylated, so malonyl-CoA concentration falls. (c) CPT-I is normally inhibited by malonyl-CoA. When malonyl-CoA levels drop, CPT-I becomes active, increasing the import of fatty acyl-CoA into the mitochondrion for β-oxidation. (d) Hepatic fatty acid synthesis rate declines because the committed step (ACC) is suppressed. Clinically, the net result is reduced hepatic triglyceride accumulation (beneficial for NAFLD) and enhanced fatty acid oxidation (improving insulin sensitivity). These metabolic shifts help lower blood glucose and lipid levels, which is precisely the therapeutic goal in type 2 diabetes management.

Question 5: CRITICAL THINKING

Cancer cells frequently overexpress fatty acid synthase (FAS) even when exogenous fatty acids are available. Propose a biochemical hypothesis for why cancer cells might rely on de novo synthesis rather than uptake, and discuss one potential complication of using FAS inhibitors as anticancer drugs.

Show answer

Rapidly proliferating cancer cells require large quantities of membrane phospholipids, signaling lipids, and lipid-modified proteins to support cell division. De novo synthesis provides a controlled, cell-autonomous supply of fatty acids whose chain length and saturation can be precisely tuned, independent of fluctuating extracellular lipid availability. Additionally, the high glycolytic flux in cancer cells (Warburg effect) generates excess cytosolic acetyl-CoA and NADPH (via the PPP), making lipogenesis thermodynamically and kinetically favorable. A potential complication of FAS inhibitors is toxicity to normal lipogenic tissues (liver, adipose, lactating mammary gland), which also depend on de novo synthesis. Moreover, cancer cells may develop resistance by upregulating fatty acid uptake transporters (e.g., CD36/FATP), scavenging lipids from the tumor microenvironment, or activating alternative lipogenic pathways, thereby bypassing the drug target.

SUMMARY

Fatty Acid Synthesis and Regulation — Summary

Summary

De novo fatty acid synthesis converts acetyl-CoA into palmitate (C16:0) in the cytosol. The citrate shuttle exports mitochondrial acetyl-CoA equivalents. Acetyl-CoA carboxylase (ACC) catalyzes the rate-limiting carboxylation to malonyl-CoA, and fatty acid synthase (FAS) carries out seven iterative cycles of condensation, reduction, dehydration, and reduction using 14 NADPH and 7 ATP. The overall cost is approximately 50 ATP-equivalents per palmitate.

Regulation occurs at three levels: allosteric (citrate activates, palmitoyl-CoA inhibits ACC), covalent (AMPK and PKA phosphorylate/inactivate ACC; insulin-driven PP2A reactivates it), and transcriptional (SREBP-1c and ChREBP upregulate lipogenic genes). Malonyl-CoA also inhibits CPT-I, preventing simultaneous β-oxidation—a hallmark of reciprocal regulation. Dysregulation of this pathway underlies metabolic diseases including NAFLD and is being targeted in cancer therapy.